In most of the cases, either the CML moves towards to the advanced phase, or BCR-ABL and CML cells show remission in more than half of the people who cease TKI treatment [4, 5]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.